Filing Flows › Cumberland Pharmaceuticals (CPIX) › Q4 2025
Cumberland Pharmaceuticals (CPIX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 9, 2026
Cumberland Pharmaceuticals (CPIX) reported revenue of $13.7M for the fourth quarter 2025 (Q4 2025), +31% from a year earlier and +65% from the quarter before. Operating margin was -10.0%, net loss $1.4M (10.4% of revenue).
Cumberland Pharmaceuticals, Q4 2025: revenue $13.7M (+31% year over year), operating margin -10.0%, net loss $1.4M, operating cash flow $3K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.7M | +65% | +31% |
| Operating profit | −$1.4M | — | — |
| Net earnings | −$1.4M | — | — |
| Operating cash flow | $3K | -98% | -100% |
What changed
Revenue was $13.7M in Q4 2025, up 31% year over year and up 65% from the previous quarter.
Operating costs exceeded revenue by $1.4M, an operating margin of -10.0%. Total costs grew 23% against revenue growth of 31%. The fastest-growing cost line was Sales & marketing (+47%). The quarter ended with a net loss of $1.4M, narrower than the previous quarter's $1.9M loss. Minority interests bore $17K of it: to shareholders the quarter was a loss of $1.4M.
Operating cash flow was $3K (down 100% year over year). Non-cash charges added back $1.0M of depreciation and amortization and $172K of share-based compensation. Working capital and other items added $218K. Capital expenditures of −$0K left free cash flow of $3K.
Questions
What was Cumberland Pharmaceuticals' revenue in the fourth quarter 2025?
Cumberland Pharmaceuticals (CPIX) reported revenue of $13.7M for the fourth quarter 2025 (Q4 2025), +31% from a year earlier and +65% from the quarter before.
Was Cumberland Pharmaceuticals profitable in the fourth quarter 2025?
Operating loss was $1.4M (-10.0% of revenue) and net loss $1.4M.